Xvivo Perfusion AB (publ)
XVIPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $822,415 | $597,542 | $415,292 | $258,386 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Cost of Goods Sold | $206,000 | $152,431 | $118,336 | $70,107 |
| Gross Profit | $616,415 | $445,111 | $296,956 | $188,279 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| R&D Expenses | $148,329 | $135,942 | $69,343 | $54,039 |
| G&A Expenses | $95,788 | $76,944 | $70,979 | $55,687 |
| SG&A Expenses | $379,770 | $309,205 | $223,377 | $153,375 |
| Sales & Mktg Exp. | $283,982 | $232,261 | $152,398 | $97,688 |
| Other Operating Expenses | -$37 | -$4,223 | -$219 | -$393 |
| Operating Expenses | $528,062 | $440,924 | $292,501 | $207,021 |
| Operating Income | $88,353 | $4,187 | $23,181 | $6,982 |
| % Margin | 10.7% | 0.7% | 5.6% | 2.7% |
| Other Income/Exp. Net | $111,595 | $90,334 | -$867 | -$317 |
| Pre-Tax Income | $199,948 | $94,521 | $22,314 | $6,665 |
| Tax Expense | $27,766 | $2,701 | $3,887 | -$1,487 |
| Net Income | $172,182 | $91,820 | $18,427 | $8,152 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS | 1.37 | 0.77 | 0.16 | 0.07 |
| % Growth | 77.9% | 381.3% | 128.6% | – |
| EPS Diluted | 1.36 | 0.77 | 0.16 | 0.07 |
| Weighted Avg Shares Out | 126,604 | 119,741 | 118,104 | 115,383 |
| Weighted Avg Shares Out Dil | 126,600 | 119,741 | 118,104 | 115,744 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $8,850 | $2,123 | $276 |
| Interest Expense | $0 | -$71,591 | $605 | $276 |
| Depreciation & Amortization | $21,496 | $76,350 | $15,803 | $32,257 |
| EBITDA | $110,902 | $172,061 | $39,211 | $39,198 |
| % Margin | 13.5% | 28.8% | 9.4% | 15.2% |